ABOS Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapeutics for the treatment of Alzheimer's and other neurodegenerative diseases. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, which is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is based in Charlottesville, Virginia.

$7.91  -0.22 (-2.71%)
As of 12/03/2021 11:32:13 EST     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Small cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  06/30/2021
Outstanding shares:  40,470,323
Average volume:  68,357
Market cap:   $306,765,048
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    00509G209
ISIN:        US00509G2093
Sedol:      BLR8WK7
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   1.41
PS ratio:   932.42
Return on equity:   -39.86%
Net income %:   -28,271.12%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy